Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 125.27 0.84% 1.04
ALNY closed up 1.84 percent on Thursday, December 5, 2019, on 1.37 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical ALNY trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.84%
New 52 Week High Strength 0.84%
Wide Bands Range Expansion 0.84%
Overbought Stochastic Strength 0.84%
Doji - Bearish? Reversal 2.70%
New 52 Week High Strength 2.70%
Multiple of Ten Bullish Other 2.70%
Wide Bands Range Expansion 2.70%
Overbought Stochastic Strength 2.70%
New 52 Week Closing High Bullish 2.37%

Older signals for ALNY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Hemophilia Huntington's Disease Spinal Muscular Atrophy Alnylam Pharmaceuticals Treatment Of Hemophilia Therapeutic Gene Modulation Hemoglobinopathies Hypercholesterolemia Acute Intermittent Porphyria Deficiency

Is ALNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicator Value
52 Week High 125.59
52 Week Low 60.27
Average Volume 716,530
200-Day Moving Average 82.60
50-Day Moving Average 92.25
20-Day Moving Average 105.56
10-Day Moving Average 117.15
Average True Range 4.39
ADX 50.99
+DI 37.85
-DI 4.34
Chandelier Exit (Long, 3 ATRs ) 112.41
Chandelier Exit (Short, 3 ATRs ) 102.11
Upper Bollinger Band 130.93
Lower Bollinger Band 80.20
Percent B (%b) 0.87
BandWidth 48.06
MACD Line 9.11
MACD Signal Line 7.53
MACD Histogram 1.5848
Fundamentals Value
Market Cap 11.4 Billion
Num Shares 91.7 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -24.26
Price-to-Sales 159.14
Price-to-Book 9.35
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 130.16
Resistance 3 (R3) 129.95 127.77 129.17
Resistance 2 (R2) 127.77 126.26 127.87 128.84
Resistance 1 (R1) 126.00 125.33 126.89 126.21 128.51
Pivot Point 123.82 123.82 124.26 123.92 123.82
Support 1 (S1) 122.05 122.31 122.94 122.26 119.95
Support 2 (S2) 119.87 121.38 119.97 119.62
Support 3 (S3) 118.10 119.87 119.29
Support 4 (S4) 118.31